United States

Genovis AB (GENOb.ST)

GENOb.ST on Stockholm Stock Exchange

22 Jul 2016
Change (% chg)

0.03kr (+1.69%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for GENOb.ST


Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer,... (more)
No analyst recommendations are available for GENOb.ST.


Beta: 0.87
Market Cap(Mil.): kr100.08
Shares Outstanding(Mil.): 55.29
Dividend: --
Yield (%): --


  GENOb.ST Industry Sector
P/E (TTM): -- 43.63 37.05
EPS (TTM): -0.54 -- --
ROI: -239.69 11.61 14.35
ROE: -244.75 13.64 15.56

BRIEF-Genovis and Promega reach agreement in patent dispute

* Genovis and Promega have reached agreement in patent dispute

Jun 30 2016

BRIEF-Genovis rights issue oversubscribed

* Issue was subscribed for about 25.4 million Swedish crowns ($3.07 million)

Jun 13 2016

BRIEF-Genovis elects Mårten Winge as Chairman

May 13 Genovis AB : * Mårten Winge elected as Chairman Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 13 2016

BRIEF-Genovis Q1 operating loss narrows to SEK 3.4 million

* Q1 net sales 3.8 million Swedish crowns ($472,044) versus 2.9 million crowns year ago

May 04 2016

BRIEF-Genovis decides on new share issue at SEK 1.25/shr

* At full subscribtion share capital will increase by up to 4.6 million Swedish crowns ($560,415.19) through issue of up to 18.4 million shares

Mar 21 2016

BRIEF-Genovis signs strategic cooperation agreement with Alphalyse A/S

* Has signed a strategic cooperation agreement with Alphalyse A/S Source text for Eikon:

Mar 17 2016

BRIEF-Genovis Q4 EBITDA loss narrows to 3.9 million Swedish crowns

* Q4 net sales 3.5 million Swedish crowns versus 2.1 million crowns year ago

Feb 15 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
Provider : GlobalData
Provider : Wright Reports
Provider : GlobalData
Provider : GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.